Leqselvi ™ (deuruxolitinib) is now available for the treatment of adults with severe alopecia areata.

Sun Pharma has introduced LEQSELVITM (deuruxolitinib) 8 mg tablets in the US for severe alopecia areata after settling a patent dispute with Incyte. Approved by the FDA and backed by strong clinical ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

The International Medical Derm Summit 2025 highlighted China's dermatological advancements, fostering global collaboration ...

The stigma of having alopecia causes more depression and anxiety than the disease itself, new research has found.

The stigma of having alopecia causes more depression and anxiety than the disease itself, new research has found.

A new study published in the Journal of American Medical Association showed that individuals with autoimmune skin diseases ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Patients with higher-severity alopecia areata (AA) have a higher prevalence and incidence of comorbid atopic dermatitis (AD), according to a study published online June 26 in the Journal of ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...